Hepatitis B virus (HBV) is currently estimated to be responsible for 290 million chronic infections globally, accounting for >800,000 deaths each year [1]. Infection is endemic among some of the world’s poorest and most vulnerable communities, exemplified by many settings across the African subcontinent. International Sustainable Development Goals set out the challenge of combating viral hepatitis, with specific targets developed by the World Health Organisation (WHO) for the elimination of these infections as a public health threat by the year 2030 [2]. For a crisis of such magnitude, with focused global targets now in place, we start from a position of surprising ignorance. A sustained lack of economic, scientific, clinical and political investment offer some explanation as to why HBV can aptly be considered a neglected tropical disease (NTD) [3]. The morbidity and mortality arising from HBV infection are predictable consequences of poverty, and we should be mindful of neglected peoples as much as of a neglected pathogen [4].

There are still gaps in our understanding of the biology of this unusual partially double-stranded DNA retrovirus [5]. For Africa, even basic observational epidemiology is poorly described, transmission routes are not properly characterised, the immunological correlates of vaccine-mediated immunity are uncertain, and there are substantial gaps in describing the distribution and clinical impact of drug resistance mutations [3,6,7]. We are further hindered by stigma and discrimination, which can be potent barriers to individual diagnosis and treatment, impede progress at population level, inhibit political advocacy, and interfere with collection of reliable data [3,8]. All of these attributes of HBV infection vary across a continent as diverse and heterogeneous as Africa; we cannot assume that a focused insight derived from one setting is universally applicable.

HBV has been chronically under-represented by funding, research, education, advocacy and clinical care, leading to a lack of robust data to underpin advances. There is a risk that this backdrop of neglect inhibits future progress – a ‘catch 22’ situation.
At present, attempts to enhance and develop progress for HBV can almost universally be criticised for their poor foundations. It is too easy for this inhibitory influence to become the status quo, and herein lies the catch-22: neglect begets neglect. This phenomenon is exemplified by an analysis of NTD research from Nigeria, reporting that most data are published in journals with no known impact factor [9]. While impact factor should be applied with caution as a measure of quality, the metric in this case certainly reflects a neglected body of work, lacking quality assurance, that does not receive recognition or generate re-use.

The WHO ‘roadmap’ that directs us towards elimination goals for NTDs recognises the need for generating and sharing high quality data [10]. Developing a similar roadmap for HBV should include a strong mandate for producing and publishing new insights, empowering the development and sharing of evidence-based observations, resources, and recommendations. Areas where there are gaps in current knowledge need to be identified and systematically advanced, with publication through routes that incorporate scientific integrity and robust peer review. This approach is enshrined in the “FAIR” data principles, reflecting the need for data to be Findable, Accessible, Interoperable and Reproducible [11].

We must also be willing to recognise and accept deficiencies in preexisting data. This means that - while caveats are made explicit and transparent, and potential limitations are recognised – we are nevertheless able to foster an environment in which advances can emerge despite a backdrop of chronic neglect. Areas of uncertainty must be allowed to benefit from an open cycle of data sharing, critique and refinement. We are otherwise at risk of continuing to suppress progress in a field that so urgently needs to flourish if we are to make meaningful strides towards 2030 targets.

In order to advance towards targets for elimination set by international Sustainable Development Goals, urgent action is needed: filling the gaps in knowledge and practice requires careful clinical and scientific scrutiny, supported by a commitment to generating and sharing high quality data.

Funding: PCM is funded by a Wellcome Trust Fellowship (grant ref 110110).
Authorship contributions: This article was conceived and written by PCM
Competing interests: PCM holds a consultancy contract with Immunocore and is an Associate Editor for BMC Infectious Diseases. The author has completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declares no further conflict of interest.

REFERENCES

1 Polaris Observatory C. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383-403. Medline:29599078 doi:10.1016/S2468-1253(18)30056-6
2 World Health Organization. Global health sector strategy on viral hepatitis, 2016-2021. WHO reference number: WHO/HIV/2016.06. http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. 2016. Accessed: 17 October 2018.
3 O’Hara GA, McNaughton AL, Maponga T, Jooste P, Ocama P, Chilengi R, et al. Hepatitis B virus infection as a neglected tropical disease. PLoS Negl Trop Dis. 2017;11:e0005842. Medline:28981505 doi:10.1371/journal.pntd.0005842
4 Potet J. BMJ Blogs. 2017. Available from: https://blogs.bmj.com/bmj/2017/04/21/combatting-neglected-tropical-diseases-much-progress-but-millions-of-patients-lack-access-to-care/. Accessed: 17 October 2018.
5 McNaughton AL, D’Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, et al. Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood. Gastroenterology. 2019;156:384-99. Medline:30268787 doi:10.1053/j.gastro.2018.07.058
6 Mokaya J, McNaughton AL, Hadley MJ, Beloukas A, Geretti AM, Goedhals D, et al. A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action. PLoS Negl Trop Dis. 2018;12:e0006629. Medline:30080852 doi:10.1371/journal.pntd.0006629
REFERENCES

7 Lemoine M, Eholie S, Lacombe K. Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach. J Hepatol. 2015;62:469-76. Medline:25457207 doi:10.1016/j.jhep.2014.10.008

8 Mokaya J, McNaughton A, Burbridge L, Maponga T, O’Hara GA, Andersson M, et al. A blind spot? Confronting the stigma of hepatitis B virus (HBV) infection - A systematic review [version 2; referees: 2 approved]. Wellcome Open Res. 2018;3:29. Medline:30483598 doi:10.12688/wellcomeopenres.14273.2

9 Okorie PN, Bockarie MJ, Molyneux DH, Kelly-Hope LA. Neglected tropical diseases: a systematic evaluation of research capacity in Nigeria. PLoS Negl Trop Dis. 2014;8:e3078. Medline:25121582 doi:10.1371/journal.pntd.0003078

10 World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases. A roadmap for implementation. 2011. https://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf. Accessed: 17 October 2018.

11 Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016;3:160018. Medline:26978244 doi:10.1038/sdata.2016.18

Correspondence to:
Philippa Matthews
Medawar Building for Pathogen Research
South Parks Road
Oxford, OX1 3SY
UK
philippa.matthews@ndm.ox.ac.uk